ARCH Venture Fund VIII Overage, L.P.'s Net Worth

$525 Million

Who is ARCH Venture Fund VIII Overage, L.P.?

ARCH Venture Fund VIII Overage, L.P. has an estimated net worth of $525 Million. This is based on reported shares across multiple companies, which include Neumora Therapeutics, Inc., Quanterix Corp, Twist Bioscience Corp, Metacrine, Inc., Unity Biotechnology, Inc., Codiak BioSciences, Inc., Sienna Biopharmaceuticals, Inc., and Homology Medicines, Inc..

SEC CIK

ARCH Venture Fund VIII Overage, L.P.'s CIK is 0001617237

Past Insider Trading and Trends

2020 was ARCH Venture Fund VIII Overage, L.P.'s most active year for acquiring shares with 16 total transactions. ARCH Venture Fund VIII Overage, L.P.'s most active month to acquire stocks was the month of August. 2020 was ARCH Venture Fund VIII Overage, L.P.'s most active year for disposing of shares, totalling 13 transactions. ARCH Venture Fund VIII Overage, L.P.'s most active month to dispose stocks was the month of August. 2023 saw ARCH Venture Fund VIII Overage, L.P. paying a total of $25,500,000.00 for 18,924,704 shares, this is the most they've acquired in one year. In 2020 ARCH Venture Fund VIII Overage, L.P. cashed out on 30,643,367 shares for a total of $0.00, their largest year based on trade value.